Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor

Clear cell renal cancer (RCC) is the tumor in which the treatment paradigm of locally advanced and metastatic disease has almost completely shifted away from immunotherapy/cytokine treatment towards antiangiogenic therapies.